Pharmacogenomics of the triazole antifungal agent voriconazole

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 861-872

  Mikus, Gerd ^a   Scholz, Ina Maria ^a   Weiss, Johanna ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

ABCB1; CYP2C19; CYP2C9; CYP3A4; metabolism; pharmacokinetics; polymorphism; voriconazole

Indexed keywords

CYTOCHROME P450 2C19; ERYTHROMYCIN; RITONAVIR; VORICONAZOLE;

AREA UNDER THE CURVE; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME SPECIFICITY; GENOTYPE; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MYCOSIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPIC VARIATION; POINT OF CARE TESTING; REVIEW;

ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; HUMANS; PHARMACOGENETICS; PYRIMIDINES; TRIAZOLES;

ASPERGILLUS; CANDIDA;

EID: 79959400397     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.18     Document Type: Review

References (65)

1. Chiou CC, Groll AH, Walsh TJ: New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 5, 120-135 (2000). (Pubitemid 30238232)
2. Patterson TF, Boucher HW, Herbrecht R et al.: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin. Infect. Dis. 41, 1448-1452 (2005). (Pubitemid 41579987)
3. Donnelly JP, De Pauw BE: Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin. Microbiol. Infect. 10(Suppl. 1), 107-117 (2004). (Pubitemid 38379956)
4. Walsh TJ, Karlsson MO, Driscoll T et al.: Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48, 2166-2172 (2004). (Pubitemid 38691615)
5. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A: Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42, 395-402 (2002). (Pubitemid 34259773)
6. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46, 201-211 (2008). (Pubitemid 351269158)
7. Andes D, Pascual A, Marchetti O: Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53, 24-34 (2009).
8. Geist MJ, Egerer G, Burhenne J, Riedel KD, Mikus G: Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob. Agents Chemother. 51, 3455-3456 (2007). (Pubitemid 350067579)
9. Mikus G, Schöwel V, Drzewinska M et al.: Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther. 80, 126-135 (2006). (Pubitemid 44160688)
10. Rengelshausen J, Banfield M, Riedel KD et al.: Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther. 78, 25-33 (2005). (Pubitemid 40956928)
11. Hafner V, Albermann N, Haefeli WE, Ebinger F: Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis. Antimicrob. Agents Chemother. 52, 4172-4174 (2008).
12. Weiss J, Ten Hoevel MM, Burhenne J et al.: CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 49, 196-204 (2009).
13. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D: Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46, 2546-2553 (2002). (Pubitemid 34793462)
14. Scholz I, Oberwittler H, Riedel KD et al.: Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br. J. Clin. Pharmacol. 68, 906-915 (2009).
15. Roffey SJ, Cole S, Comby P et al.: The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31, 731-741 (2003). (Pubitemid 36617661)
16. Levêque D, Nivoix Y, Jehl F, Herbrecht R: Clinical pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents 27, 274-284 (2006).
17. Hyland R, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31, 540-547 (2003). (Pubitemid 36444162)
18. Yanni SB, Annaert PP, Augustijns P et al.: Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab. Dispos. 36, 1119-1125 (2008). (Pubitemid 351717470)
19. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H: Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem. Pharmacol. 73, 2020-2026 (2007). (Pubitemid 46677908)
20. Jeong S, Nguyen PD, Desta Z: Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob. Agents Chemother. 53, 541-551 (2009).
21. Bruggemann RJ, Alffenaar JW, Blijlevens NM et al.: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48, 1441-1458 (2009).
22. Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958 (2002). (Pubitemid 35168437)
23. Ferguson RJ, De Morais SM, Benhamou S et al.: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284, 356-361 (1998). (Pubitemid 28109566)
24. Sim SC, Risinger C, Dahl ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006). (Pubitemid 43069582)
25. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 69, 222-230 (2010).
26. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D: No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br. J. Clin. Pharmacol. 56(Suppl. 1), 30-36 (2003). (Pubitemid 37491731)
27. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M: Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Pharmacol. Ther. 75, 587-588 (2004). (Pubitemid 38746611)
28. Karlsson MO, Lutsar I, Milligan PA: Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53, 935-944 (2009).
29. Johnson HJ, Han K, Capitano B et al.: Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob. Agents Chemother. 54, 852-859 (2010).
30. Berge M, Guillemain R, Tregouet DA et al.: Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur. J. Clin. Pharmacol. 37(3), 253-260 (2011).
31. Matsumoto K, Ikawa K, Abematsu K et al.: Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int. J. Antimicrob. Agents 34, 91-94 (2009).
32. Wang G, Lei HP, Li Z et al.: The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur. J. Clin. Pharmacol. 65, 281-285 (2009).
33. Berge M, Guillemain R, Boussaud V et al.: Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl. Infect. Dis. 11, 211-219 (2009).
34. Hassan A, Burhenne J, Riedel K-D et al.: Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther. Drug Monit. 33(1), 86-93 (2011).
35. Shi HY, Yan J, Zhu WH et al.: Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur. J. Clin. Pharmacol. 66, 1131-1136 (2010).
36. Shakeri-Nejad K, Stahlmann R: Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin. Pharmacother. 7, 639-651 (2006).
37. Geist MJ, Egerer G, Burhenne J, Mikus G: Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob. Agents. Chemother. 50, 3227-3228 (2006). (Pubitemid 44396448)
38. Wojnowski L: Genetics of the variable expression of CYP3A in humans. Ther. Drug Monit. 26, 192-199 (2004). (Pubitemid 38501217)
39. Schuetz EG, Relling MV, Kishi S et al.: PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol. Rev. 56, 159 (2004).
40. Daly AK: Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 45, 13-31 (2006). (Pubitemid 43145013)
41. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001). (Pubitemid 32268418)
42. Levin MD, Den Hollander JG, van der Holt B et al.: Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J. Antimicrob. Chemother. 60, 1104-1107 (2007).
43. Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T: Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br. J. Clin. Pharmacol. 69, 593-597 (2010).
44. Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55, 3-29 (2003). (Pubitemid 36078452)
45. Sauna ZE, Kim IW, Ambudkar SV: Genomics and the mechanism of P-glycoprotein (ABCB1). J. Bioenerg. Biomembr. 39, 481-487 (2007).
46. Wakiec R, Prasad R, Morschhauser J, Barchiesi F, Borowski E, Milewski S: Voriconazole and multidrug resistance in Candida albicans. Mycoses 50, 109-115 (2007).
47. Gupta A, Unadkat JD, Mao Q: Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J. Pharm. Sci. 96, 3226-3235 (2007).
48. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH: Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 51, 289-295 (1996). (Pubitemid 26422976)
49. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M: Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76, 27-33 (1998). (Pubitemid 28304939)
50. Miura J, Obua C, Abbo C, Kaneko S, Tateishi T: Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur. J. Clin. Pharmacol. 65, 319-320 (2009).
51. Garcia-Barcelo M, Chow LY, Kum Chiu HF et al.: Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Clin. Chem. 45, 2273-2274 (1999).
52. Sugimoto K, Uno T, Yamazaki H, Tateishi T: Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br. J. Clin. Pharmacol. 65, 437-439 (2008). (Pubitemid 351316919)
53. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10, 43-49 (2009).
54. Pedersen RS, Brasch-Andersen C, Sim SC et al.: Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol. 66, 1199-1205 (2010).
55. Purkins L, Wood N, Kleinermans D, Love ER: No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br. J. Clin. Pharmacol. 56(Suppl. 1), 62-68 (2003). (Pubitemid 37491736)
56. Purkins L, Wood N, Kleinermans D, Nichols D: Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1), 51-55 (2003). (Pubitemid 37491734)
57. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A: Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol. 56(Suppl. 1), 37-44 (2003). (Pubitemid 37491732)
58. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D: Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1), 17-23 (2003). (Pubitemid 37491729)
59. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD: Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl. 1), 10-16 (2003). (Pubitemid 37491728)
60. Wood N, Tan K, Purkins L et al.: Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1), 56-61 (2003). (Pubitemid 37491735)
61. Dowell JA, Schranz J, Baruch A, Foster G: Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. 45, 1373-1382 (2005). (Pubitemid 41642440)
62. Liu P, Foster G, Gandelman K et al.: Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob. Agents Chemother. 51, 3617-3626 (2007). (Pubitemid 47519352)
63. Liu P, Foster G, Labadie RR, Gutierrez MJ, Sharma A: Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J. Clin. Pharmacol. 48, 73-84 (2008). (Pubitemid 350292275)
64. Liu P, Foster G, Labadie R, Somoza E, Sharma A: Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob. Agents Chemother. 51, 110-118 (2007). (Pubitemid 46047695)
65. Andrews E, Damle BD, Fang A et al.: Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br. J. Clin. Pharmacol. 65, 531-539 (2008). (Pubitemid 351365140)